As of 2026-02-11, the EV/EBITDA ratio of Flexion Therapeutics Inc (FLXN) is -7.35. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. FLXN's latest enterprise value is 575.17 mil USD. FLXN's TTM EBITDA according to its financial statements is -78.25 mil USD. Dividing these 2 quantities gives us the above FLXN EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 14.8x - 15.2x | 15.0x |
| Forward P/E multiples | 18.2x - 25.2x | 20.2x |
| Fair Price | (85.43) - (72.71) | (83.10) |
| Upside | -432.6% - -383.0% | -423.5% |
| Date | EV/EBITDA |
| 2026-02-10 | -7.35 |
| 2026-02-06 | -7.34 |
| 2026-02-05 | -7.32 |
| 2026-02-04 | -7.33 |
| 2026-02-03 | -7.33 |
| 2026-02-02 | -7.34 |
| 2026-01-30 | -7.33 |
| 2026-01-29 | -7.33 |
| 2026-01-28 | -7.33 |
| 2026-01-27 | -7.34 |
| 2026-01-26 | -7.34 |
| 2026-01-23 | -7.33 |
| 2026-01-22 | -7.34 |
| 2026-01-21 | -7.33 |
| 2026-01-20 | -7.31 |
| 2026-01-16 | -7.32 |
| 2026-01-15 | -7.32 |
| 2026-01-14 | -7.32 |
| 2026-01-13 | -7.32 |
| 2026-01-12 | -7.32 |
| 2026-01-09 | -7.31 |
| 2026-01-08 | -7.31 |
| 2026-01-07 | -7.31 |
| 2026-01-06 | -7.31 |
| 2026-01-05 | -7.30 |
| 2026-01-02 | -7.28 |
| 2025-12-31 | -7.28 |
| 2025-12-30 | -7.29 |
| 2025-12-29 | -7.28 |
| 2025-12-26 | -7.28 |
| 2025-12-24 | -7.28 |
| 2025-12-23 | -7.44 |
| 2025-12-22 | -7.43 |
| 2025-12-19 | -7.43 |
| 2025-12-18 | -7.43 |
| 2025-12-17 | -7.41 |
| 2025-12-16 | -7.42 |
| 2025-12-15 | -7.42 |
| 2025-12-12 | -7.42 |
| 2025-12-11 | -7.43 |
| 2025-12-10 | -7.43 |
| 2025-12-09 | -7.41 |
| 2025-12-08 | -7.41 |
| 2025-12-05 | -7.42 |
| 2025-12-04 | -7.42 |
| 2025-12-03 | -7.42 |
| 2025-12-02 | -7.41 |
| 2025-12-01 | -7.40 |
| 2025-11-28 | -7.41 |
| 2025-11-26 | -7.41 |